

# Using quantitative MRI to track cerebral damage in multiple sclerosis: a longitudinal study

Nora Vandeleene<sup>a</sup>, Camille Guillemain<sup>a,b</sup>, Solène Dauby<sup>a,c</sup>, Florence Requier<sup>a,b</sup>, Maëlle Charonitis<sup>a,b</sup>, Daphne Chylinski<sup>a,b</sup>, Evelyne Balteau<sup>a</sup>, Pierre Maquet<sup>a,c</sup>, Emilie Lommers<sup>a,c\*</sup>, Christophe Phillips<sup>a,d\*</sup>

<sup>a</sup> GIGA CRC in vivo Imaging, University of Liège, Liège, Belgium

<sup>b</sup> Psychology and Cognitive Neuroscience Research Unit, University of Liège, Liège, Belgium

<sup>c</sup> Clinical Neuroimmunology Unit, Neurology Department, CHU Liège, Belgium

<sup>d</sup> GIGA in silico Medicine, University of Liège, Liège, Belgium

\* These authors equally contributed to the work.

**Corresponding author:** Christophe PHILLIPS  
GIGA – CRC in vivo imaging B30  
Allée du 6 août  
4000 Liège  
Belgium

## **Word count:**

Main text: 2685; Methods: 2367 (Total: 5052); Abstract: 320

## **Abbreviations:**

**ARoC:** Annual Rate of Change, **BPF:** Brain Parenchymal Fraction, **CDP:** Confirmed Disability Progression, **cmMRI:** Conventional Magnetic Resonance Imaging, **CNS:** Central Nervous System, **GMF:** Grey Matter Fraction, **GLMM:** General Linear Mixed Model, **LF:** Lesion Fraction, **MPM:** Multiparameter mapping, **MRI:** Magnetic Resonance Imaging, **MS:** Multiple Sclerosis, **MT:** Magnetization Transfer, **MTR:** Magnetization Transfer Ratio, **MTsat:** Saturated Magnetization Transfer, **NABT:** Normal Appearing Brain Tissue, **NACGM:** Normal Appearing Cortical Grey Matter, **NADGM:** Normal Appearing Deep Grey matter, **NAWM:** Normal Appearing White Matter, **NEDA-3:** No Evidence of Disease Activity, **RRMS:** Relapsing-Remitting Multiple Sclerosis, **PD:** Proton Density, **PMS:** Progressive Multiple Sclerosis, **qMRI:** Quantitative Magnetic Resonance Imaging, **R1:** Longitudinal Relaxation Rate (1/T1), **R2\*:** Transverse Relaxation Rate (1/T2\*), **TIV:** Total Intracranial Volume, **TPM:** Tissue Probability Map, **US:** Unified Segmentation, **USWL:** Unified Segmentation with Lesion

## 37 **Abstract**

38 Objectives:

39 Contrary to conventional MRI (cMRI), quantitative MRI (qMRI) quantifies tissue  
40 physical microstructural properties and improves the characterization of cerebral  
41 damages in relation with various neurological diseases. With a multi-parameter  
42 mapping (MPM) protocol, 4 parameter maps are constructed: saturated magnetization  
43 transfer (MTsat), proton density (PD), longitudinal relaxation (R1) and effective  
44 transverse relaxation (R2\*) rates, reflecting tissue physical properties associated with  
45 iron and myelin contents. Here, we used qMRI to investigate the microstructural  
46 changes happening over time in multiple sclerosis (MS).

47

48 Methods:

49 Seventeen MS patients (age 25-65, 11 RRMS) were scanned on a 3T MRI, with at least  
50 one year separation between two acquisition sessions, and the evolution of their  
51 parameters was evaluated within several tissue classes: normal appearing white  
52 matter (NAWM), normal appearing cortical and deep gray matter (NACGM and  
53 NADGM) as well as focal white matter (WM) lesions. Brain tissue segmentation was  
54 performed using US-with-Lesion, an adapted version of the Unified Segmentation (US)  
55 algorithm accounting for the lesion tissue class, based on qMRI and FLAIR images. An  
56 individual annual rate of change for each qMRI parameter was computed, and its  
57 correlation to clinical status was evaluated. As for WM plaques, three areas were  
58 defined within them. A Generalized Linear Mixed Model (GLMM) tested the effect of  
59 area and time points, as well as their interaction on each median qMRI parameter  
60 value.

61

62 Results:

63 Patients with a better clinical evolution showed positive annual rate of change in MT  
64 and R2\* within NAWM and NACGM, suggesting repair mechanisms in terms of  
65 increased myelin content and/or axonal density. When examining focal WM lesions,  
66 qMRI parameters within surrounding NAWM showed modification in terms of  
67 reduction in MT, R1 and R2\* combined with increased of PD even before any focal  
68 lesion is visible on conventional FLAIR MRI.

69

70 Conclusion:

71 The results illustrate the benefit of multiple qMRI data in monitoring subtle changes  
72 within normal appearing brain tissues and plaque dynamics in relation with tissue  
73 repair or disease progression.

74

75 Keywords:

76 Quantitative MRI, relaxometry, longitudinal analysis, multiple sclerosis.

77

78

## 79        **1. Introduction**

80        Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS).

81        The course of the disease may reflect the expression of two clinical phenomena, relapses of

82        acute neurological symptoms followed by partial or complete recovery (remission), and

83        progression, which refers to the steady and irreversible worsening of the clinical status.

84        Relapses are mainly the expression of acute, focal, disseminated and recurrent inflammation

85        occurring within the CNS (i.e., plaques). Plaques are the pathological hallmark of MS and

86        harbor variable degrees of inflammation, demyelination, gliosis and axonal injury [1, 2].

87        Plaques are not restricted to the white matter (WM), but are also present in the cortex and

88        deep grey matter (GM) [3-5]. The progressive accumulation of disability principally correlates

89        with the early, diffuse and chronic inflammation within the normal appearing white matter

90        (NAWM) and grey matter (NAGM) that is ultimately responsible for diffuse neuro-axonal loss

91        and neurodegeneration [3, 4, 6]. By contrast, effective repair mechanisms can occur within

92        focal lesions but probably also in normal appearing brain tissue (NABT) [7]. However, our

93        understanding of these complex processes is still fragmentary. The difficulty of acquiring

94        histopathological data on MS patients at various stages of the disease makes it challenging to

95        describe the time course of injury and potential repair mechanisms in MS. Consequently, there

96        is an important need for new imaging techniques to improve in-vivo monitoring of lesion

97        formation, progression and repair in MS [8].

98        Conventional MRI (cMRI) readily depicts focal WM lesions on T2/FLAIR sequences and is able

99        to distinguish between acute and allegedly chronic lesions, primarily on the evidence of blood-

100        brain barrier breakdown, as indicated by contrast enhancement. T2-hyperintensities in cMRI

101        constitute the keystone of McDonald diagnostic criteria [9] and also make an important

102        contribution to the monitoring of WM lesion burden. Unfortunately, cMRI sequences are not

103 able to efficiently assess cortical lesions or detect diffuse changes in NABT. This shortcoming  
104 is particularly apparent in the poor correlation of imaging results with short and long-term  
105 clinical outcomes [10]. Quantitative MRI (qMRI) potentially overcomes these limitations by  
106 quantifying physical microstructural properties of cerebral tissue in standardized units.  
107 Nevertheless, there exist challenging issues in performing longitudinal qMRI protocols. While  
108 qMRI is theoretically independent of the scanner used for acquisition as the parametric  
109 images rely on physical measurements of brain tissues, in reality the reproducibility is lower  
110 than expected, especially for semi-quantitative MT maps [11, 12]. Despite that, longitudinal  
111 analysis can still be accurate when identical sequences are used across scanning time points.  
112 In addition, qMRI is more sensitive but also more specific to microstructural properties of CNS  
113 tissues. Magnetization transfer ratio (MTR) was regularly linked to cerebral macromolecular  
114 content detected by a greater percentage loss of magnetization in voxels with a higher myelin  
115 content and axons density [13-15]. Post-mortem studies comparing the relative contribution  
116 of these two factors indicate that myelin has a stronger and more direct influence on MTR  
117 than the axonal density, which is considered as a T1-dependent effect. Tissue water content  
118 (inflammation, edema...), another T1-dependent effect, also accounts for MTR variability [14,  
119 16, 17]. However, the MT saturation (MTsat) map offers a measure which, unlike MTR, is  
120 minimally affected by longitudinal relaxation and B1 mapping inhomogeneities [18],  
121 increasing its sensitivity to myelin content. Moreover, the brain contrast to noise ratio is larger  
122 for the MTsat map than for MTR, thus improving brain tissue segmentation in healthy subjects  
123 [14, 19]. Regarding the transverse relaxation time  $T2^*$ , this measure reflects the effective  
124 decay of transverse magnetization  $T2$ , when considering intra-voxel magnetic field  
125 inhomogeneities. In the CNS, paramagnetic iron and diamagnetic myelin generate microscopic  
126 field gradients, thus shortening  $T2^*$  and increasing the  $R2^*$  ( $1/T2^*$ ) relaxation rate. Orientation

127 and density of myelin fibers are also a determining factor of  $R2^*$  values [20-22]. Concerning  
128 the longitudinal relaxation rate  $R1$  ( $1/T1$ ) in the CNS, its three major determinants are tissue  
129 myelination and associated axons, iron and extracellular water contents [22-24]. Finally,  
130 proton density (PD) mostly reflects the free water content of the brain [25].

131 We have previously shown that a multivariate qMRI approach is useful to assess NABT  
132 microstructural alteration in a cross-sectional study comparing MS patients to healthy controls  
133 [26, 27]. Because each qMRI parameter is differently sensitive to histologically measured iron  
134 and myelin contents, this approach constitutes a fundamental tool for longitudinal *in-vivo*  
135 monitoring of MS lesions and NABT evolution at the tissue microstructural level.

136 In this longitudinal study, we investigate the evolution of four simultaneously acquired qMRI  
137 parameters (MTsat, PD,  $R1$ ,  $R2^*$ ) within NABT and WM lesions of 17 MS patients (relapsing  
138 remitting (RRMS) and progressive MS (PMS)) who were scanned two or three times with at  
139 least a one-year interval, following the same multi-parameter mapping (MPM) protocol at 3  
140 Tesla [13, 28]. Segmentation of different cerebral tissue classes was computed using an  
141 advanced segmentation technique called Unified Segmentation with Lesion (USwL), an  
142 updated version of the traditional Unified Segmentation (US) algorithm from SPM. This  
143 pipeline accounts for lesions and relies on quantitative parameter maps rather than the  
144 standard weighted images.

145 Here, we assessed the time course of parameter values in several tissue classes: NAWM,  
146 normal appearing cortical and deep GM (NACGM and NADGM) as well as focal WM lesions. In  
147 addition, we related the changes in NABT to clinical course.

148

## 149        **2. Materials and methods**

### 150                **2.1 Population**

151        Seventeen patients, recruited at the specialized MS outpatient clinic of the CHU Liège,  
152        Belgium, with a diagnosis of MS according to the McDonald criteria 2010 [29], were gathered  
153        from two studies: ten of them were part of the work reported by Lommers et al. 2019 [26],  
154        the other seven were recruited from another MS study taking place at the GIGA Cyclotron  
155        Research Centre – In Vivo Imaging (Liège, Belgium). Both were approved by the local ethics  
156        committee (approval numbers B707201213806 and B707201835630, respectively). All  
157        patients were followed up and scanned twice on the same 3T MRI scanner, every 1 to 3 years.  
158        For each of the 17 MS patients, data from two MRI sessions were available, at T0 and T1. This  
159        cohort included 11 RRMS patients and 6 (primary and secondary) PMS. Thirteen were  
160        receiving disease-modifying treatments (DMTs). The patients' median age was 36 years  
161        (range: 25-65) and the median time interval between two scans was 30 months (range: 14-  
162        61). Demographic data appears in Table 1. Extended individual information appears in  
163        Supplementary data.

164

165

166

	<b>All Patients (n = 17)</b>	
<b>Age, y, median (range)</b>	36 (25-65)	
<b>Sex, F/M</b>	7/10	
<b>MS phenotype (RRMS/MS)</b>	11/6	
<b>Baseline disease duration, y, median (range)</b>	3.4 (0.3-28)	
<b>Baseline EDSS, median (range)</b>	2.5 (1-6.5)	
<b>Baseline number of relapses, median (range)</b>	<b>RRMS:</b> 2 (1-5)	<b>PMS:</b> N/A
<b>Disease-modifying treatment</b>	<b>RRMS:</b> First line, n: 5 Second line, n: 6	<b>PMS:</b> Ocrelizumab, n: 2 None, n: 4

167

168

**Table 1:** Demographic data of the study sample

169

## 2.2 MR image acquisition

170

MRI data were acquired on a 3T whole-body MRI-scanner (Magnetom Prisma, Siemens

171

Medical Solutions, Erlangen, Germany). The whole-brain MRI acquisitions included a multi-

172

parameter mapping protocol (MPM), from which one can simultaneously estimate

173

(semi)quantitative maps of magnetization transfer saturation (MTsat), proton density (PD),

174

transverse relaxation (R1) and effective longitudinal relaxation (R2\*). This protocol arising

175

from an international collaborative effort [13, 28], has already been used to study brain

176

microstructure in various conditions including normal aging [28, 30, 31], brain tumor [32],

177

Parkinson's disease [33-35] as well as MS. It consists of three co-localized 3D multi-echo fast

178

low angle shot (FLASH) acquisitions at 1mm<sup>3</sup> resolution and two additional calibration

179

sequences to correct for inhomogeneities in the RF transmit field [36, 37]. The FLASH datasets



180 were acquired with predominantly PD, T1 and MT weighting, referred to in the following as  
181 PDw, T1w and MTw echoes. All three had high bandwidth to minimize off-resonance and  
182 chemical shift artifacts. Volumes were acquired in 176 sagittal slices using a 256x224 voxel  
183 matrix. GRAPPA parallel imaging was combined with partial Fourier acquisition to speed up  
184 acquisition time to approximately 20 min. An additional FLAIR sequence was recorded with  
185 spatial resolution 1mm<sup>3</sup> and TR/TE/TI=5000ms/516ms/1800ms. Extra B1 field mapping images  
186 (transmit B+ and receive B- fields) were also acquired to reduce spatial heterogeneities related  
187 to B1 effect. This was essential for proper quantification of T1 (or  $R1=1/T1$ ) in particular.  
188 Finally, B0 field mapping images, corresponding to both magnitude images and pre-subtracted  
189 phase image, were acquired for image distortions corrections. A summary of the acquisition  
190 parameters appears in Supplementary data.

191

## 192 **2.3 MR image processing**


193 All data processing was performed in Matlab (The MathWorks Inc., Natick, MA, USA) using  
194 SPM12 ([www.fil.ion.ucl.ac.uk/spm](http://www.fil.ion.ucl.ac.uk/spm)) and three additional dedicated SPM extensions: the  
195 Lesion Segmentation Tool (LST) version 1.2.3 ([www.statisticalmodelling.de/lst.html](http://www.statisticalmodelling.de/lst.html)) [38], the  
196 “quantitative MRI and in vivo histology using MRI” toolbox (hMRI, <http://hmri.info>) [13], and  
197 “US-with-Lesion” tool (USwL, <https://github.com/CyclotronResearchCentre/USwLesion>).

198 Quantitative maps - MTsat, PD, R1 and R2\*- were estimated using the hMRI toolbox. T1w,  
199 PDw and MTw images acquired at multiple echo times (TE) were extrapolated to TE=0 to  
200 increase signal-to-noise ratio and remove the otherwise remaining R2\* bias [13, 26, 39]. The  
201 TE=0 extrapolated MTw, PDw and T1w images were used to calculate MT saturation, R1 and  
202 apparent signal amplitude A\* maps. PD maps were derived from A\* maps, which are  
203 proportional to proton density. All quantitative maps were corrected for inhomogeneities

204 from local RF transmit field (B1+), and R1 quantitative maps were further corrected for  
205 imperfect RF spoiling using the strategy of Preibisch and Deichmann [40]. The receive bias field  
206 map (B1-) was used to correct PD maps for instrumental biases. The R2\* map was estimated  
207 from all three multi-echo series (MTw, PDw and R1w) using the ESTATICS model [39].  
208 For all sessions, spatial preprocessing involved different steps (Figure 1) after generating  
209 quantitative maps using the hMRI toolbox: within-patient registration brought the two serial  
210 MR data sets into the individual T0 space, using the longitudinal registration tool from SPM  
211 [41]. For each individual patient, a preliminary WM lesion mask was generated based on FLAIR  
212 and T1w images by the lesion growth algorithm implemented in the LST toolbox [38], followed  
213 by manual corrections by an MS expert (EL) to remove aberrant/artefactual lesion detections  
214 [26]. The images were then segmented using the USwL toolbox, which consists of an extended  
215 version of the traditional Unified Segmentation (US) algorithm [42] and includes an additional  
216 tissue class representing the WM lesion(s). The USwL method internally generates a subject-  
217 specific extended set of tissue probability maps (TPM) [43]: an extra tissue class, based on the  
218 smoothed preliminary lesion mask warped into template space (using cost function masking  
219 during normalization [44]), is added to account for the lesion, and the original white matter  
220 prior map is updated accordingly [45]. The grey matter TPM was not updated due to a very  
221 low number of lesions present in the cortical ribbon. Multi-channel segmentation was  
222 conducted, using MTsat, PD, R1 and FLAIR images. This pipeline did not use the PD-, T1- and  
223 MT-weighted images acquired for the MPM maps construction, but the parametric maps  
224 themselves instead. In this way, voxels do not depict MR intensities but rather physical  
225 quantitative parameters. The method generated the segmented tissue classes (*a posteriori*  
226 tissue, including lesion, probability maps), as well as spatial warping into standard template  
227 space. The preliminary lesion mask was used as input for the first session data (at T0) then the

228 *a posteriori* lesion map generated at this initial step served as prior to the subsequent session  
229 (at T1).  
230 Segmentation teased out the different tissue classes of interest: NAWM, NACGM and NADGM,  
231 as well as WM lesions. To analyze the microstructure within those tissue classes, *a posteriori*  
232 tissue maps were binarized and tissue-specific independent masks were constructed: each  
233 voxel is assigned to one single tissue class with the highest probability for that voxel (provided  
234 that this probability was above 0.2). The lesion binary mask was further cleaned for lesions  
235 <10mm<sup>3</sup> which likely resulted from segmentation errors. Finally, binarized tissue class masks  
236 were in turn applied on the MPM maps to extract voxel values inside them.  
237

238



239

240

241 **Figure 1:** Chartflow of data creation and processing (see text). MPM maps were

242 created with the hMRI-toolbox, FLAIR images were directly acquired for both sessions

243 (T0 and T1). A preliminary mask was constructed based on T0 FLAIR. All images (MPM

244 and FLAIR, T0 and T1) were co-registered to the MPM T0 space. Segmentation using

245 USwL allowed to isolate the different tissue classes.

## 246                    **2.4 Brain volume change**

247    Volumetric changes were investigated using the USwL *a posteriori* tissue probability maps. The  
248    following measures of brain volume were computed for each session of each participant: (1)  
249    Total intra-cranial volume (TIV)=volume (NAWM + GM + CSF + lesions), (2) brain parenchymal  
250    fraction (BPF)=volume (NAWM + GM + lesions)/TIV, (3) GM fraction (GMF)=volume (GM)/TIV,  
251    and (4) lesion fraction (LF)=volume (lesion)/TIV. The percentage of change between both  
252    scanning sessions was evaluated for each volumetric measurement, then annualized changes  
253    were computed by dividing these measures by scan intervals (in years). Results were directly  
254    analysed with a t-test (testing if significantly different from 0 at  $p < .05$ ), but also in the same  
255    way as the normal-appearing tissues MR parameters in relation to the patients' clinical status  
256    (see next section).

## 257                    **2.5 Analysis of normal-appearing tissues**

258    The median value of quantitative MRI parameters was extracted from the three normal-  
259    appearing tissues (NAWM, NACGM and NADGM), and an individual annual rate of change  
260    (ARoC) was computed for each parameter in each tissue class, based on the initial and final  
261    values and accounting for the time interval (in years) between scans. This rate of change in  
262    qMRI parameters served as dependent variable in a general linear model testing the effect of  
263    clinical status:

$$264 \qquad Y = \beta_0 + \beta_1 X_{status} + \epsilon$$

265  
266     $Y$  is the ARoC for a qMRI parameter and tissue class,  $\beta$ 's are the regression parameters  
267    corresponding to the associated regressor (with  $\beta_0$  the intercept), and  $\epsilon$  the residuals.  $X_{status}$   
268    is a binary categorical variable representing the patient's disease activity status: a status score  
269    of 1 was assigned to patients stable or improving from T0 to T1.

270 This patient status  $X_{status}$  was derived from one of two scores of disease activity. For  
271 evaluating RRMS patients, NEDA-3 (No Evidence of Disease Activity [46]), a composite of three  
272 related measures of disease activity, was used. A score of 0 was assigned in the presence of  
273 new clinical relapses and/or MRI activity (new or enlarged lesions visible on FLAIR T2 or  
274 Gadolinium-enhanced images) and/or disability progression based on Expanded Disability  
275 Status Scale (EDSS). For the PMS patients, disability progression captured by sustained EDSS  
276 changes over 6 months (Confirmed Disability Progression [47] at 6 months) indicated disability  
277 progression, resulting in a score of 0. For both RRMS and PMS patients, disability progression  
278 was defined as a 1.0 point increase if the EDSS score was  $\leq 4.0$  at baseline and as a 0.5 point  
279 increased if the baseline EDSS score was  $> 4.0$ . The threshold of 4.0 was proposed in this study  
280 because it is considered as a milestone regarding ambulatory performance. NEDA-3 and 6-  
281 month CDP were evaluated at mid- and end-scanning interval, and a final status score of 0 was  
282 given only to patients for which disease activity or progression was noted in both cases,  
283 indicating a clear progression of the disease over the whole interscan interval.

284 The influence of several clinical measurements such as 25 FWT, 9HPT and SDMT was also  
285 considered to refine the evaluation of disease activity. However complete data were lacking  
286 for several patients. Moreover, when available, these additional clinical parameters did not  
287 modify the final  $X_{status}$ .

288 Permutation tests were employed for inferences [48]. R-squared value was tested against  
289 computed statistics after permutation of the data. For a number  $n$  of permutations, the  
290  $X_{status}$  values were randomly shuffled (constructing a new regressor written  $X_{status}^{\pi}$ ), tested  
291 against the unchanged response  $Y$ , and generating each time a permuted R-squared value  
292 (noted  $R_{\pi}$ ,  $R_{obs}$  being the true R-squared value computed without permutation of the data).

293 The condition  $X_{status} \neq X_{status}^{\pi}$  is verified at each permutation. After  $n$  permutations (with  $n$   
294 = 5000 in this study), a  $p$ -value was computed based on the following formula:

295 
$$p = \frac{\#(R_{\pi} > R_{obs})}{n + 1}$$

296 which estimates the probability of obtaining  $R_{obs}$  under the null hypothesis that  $Y$  is not  
297 correlated to  $X_{status}$ . The null hypothesis is rejected if  $p < .05$  FDR-corrected for multiple  
298 comparisons [49], for the 12 tests performed (3 tissue classes with 4 qMRI parameters).

299 Two-tailed t-tests were applied *post-hoc* on the significant results of permutation tests to  
300 compare the ARoC distribution between disease status, i.e.,  $X_{status} = 0$  against  $X_{status} = 1$ .  
301 Inferences were conducted at a significance level of .05.

302 The same pipeline was applied to the brain volumetric changes (BPF, GMF and LF) to test their  
303 correlation to the disease activity status.

304


## 305 **2.6 Analysis of lesions and peripheral tissues**

306 For white matter lesions analysis, we did not use ARoC but exploited directly the qMRI  
307 parameters voxel values. Importantly, with USwL, the prior lesion mask is only used in a  
308 probabilistic way and the estimated posterior lesion map, obtained using MTsat, PD, R1 and  
309 FLAIR images, typically showed more extended lesion than clinically visible on the FLAIR image  
310 alone, as obtained with LST.

311 Therefore, we separated focal lesions clinically detected on FLAIR images from their peripheral  
312 regions detected on qMRI maps. Two different peripheral regions were considered: one for  
313 each time point (T0 and T1). Therefore, at T0, three distinct lesion-related regions were  
314 isolated:

- 315 • The lesions, as clinically defined, corresponding to hyperintensity on conventional FLAIR  
316 MR image acquired at T0 (referred to as 'focal FLAIR lesion').

- 317 • The peripheral region detected on qMRI maps at T0, not including the FLAIR lesion  
318 (referred to as 'initial peripheral lesion').
- 319 • The peripheral region detected with the qMRI maps at T1, computed by masking out the  
320 T1 lesion mask with the T0 lesion mask (referred to as 'later peripheral lesion'). This region  
321 allows us to determine whether its microstructure at T0 forebodes a full-blown plaque,  
322 detectable during follow up.
- 323 The three areas were compared between each other and with NAWM, in order to characterize  
324 them on a microstructural basis (Figure 2). Only enlarging lesions were considered for these  
325 comparisons.



326

327 **Figure 2:** Schematic illustration of the NAWM and 3 lesions-related areas: Focal  
328 FLAIR lesion (dark gray area), Initial peripheral lesion detected at T0 (medium  
329 gray area), Later peripheral lesion detected at T1 (dashed, left, and light gray,  
330 right, area)

331



332 NAWM region consisted of all white matter voxels which did not belong to any of the three  
333 lesion-related regions. The four areas were independent as no voxel could belong to more  
334 than one class at the same time.

335 For all participants, MTsat, PD, R1 and R2\* median values were extracted from each lesion  
336 area, considering lesions individually (between 2 and 66 measurements per subject). Similarly,  
337 the median qMRI values within NAWM were also extracted (one measurement per subject).  
338 These values were extracted from T0 and T1 scans separately. Statistical analyses were  
339 performed in SAS 9.4 (SAS Institute, Cary, NC). None of the qMRI parameter was normally  
340 distributed, therefore we applied a log transformation on each of them prior to statistical  
341 analysis. For each qMRI parameter, a separate Generalized Linear Mixed Model (GLMM)  
342 tested the effect of areas (NAWM and the three lesion-related areas), and time points (T0 and  
343 T1), as well as their interaction (i.e., area\*time), on the median qMRI parameter value, with a  
344 first-order autoregressive variance/covariance model and participants as a random factor  
345 (intercept). The degrees of freedom were estimated using Kenward-Roger's method.  
346 Statistical significance was estimated at  $p < .05$  after adjustment for multiple comparison  
347 using Tukey's procedure.

### 348 **3. Results**

#### 349 **3.1 Volume changes**


350 BPF annually decreased between T0 and T1 by  $-0.67 \pm 1.12\%$  (significantly different from zero;  
351 paired-sample t-tests;  $t(16) = 2.57; p = .0204$ ) whereas LF increased by  $22.88 \pm 26.13\%$   
352 ( $t(16) = -3.70; p = .0019$ ). GMF non-significantly decreased by  $-0.30 \pm 1.44\%$ .

353

354 **3.2 Analysis of normal-appearing tissues**

355 As expected, changes in MTsat and R2\* within NABT between T0 and T1 varied across subjects

356 (Figure 3). PD and R1 exhibited similar behaviors, see Supplementary data.



357  
 358 **Figure 3:** Line plots illustrating individual AROCs for MTsat (left) and R2\* (right) in NAWM.

359 Each line corresponds to one subject. Dotted lines represent increasing rates.

360  
 361 At the group level, with the GLM analysis and permutation inference, we observed that the  
 362 AROc of MTsat and R2\* positively regressed with disease status as follows (Table 2): MTsat in  
 363 NAWM and NACGM and R2\* in NAWM significantly increase in patients who fare well  
 364 ( $X_{status} = 1$ ).

365

366

	NAWM	NACGM	NADGM
<b>MT</b>	<b>0.039 (.011)*</b>	<b>0.017 (.007)*</b>	0.004 (.749)
<b>PD</b>	-0.018 (.670)	0.405 (.225)	0.250 (.552)
<b>R1</b>	0.009 (.139)	0.004 (.471)	0.010 (.111)
<b>R2*</b>	<b>0.295 (.002)*</b>	0.121 (.092)	0.066 (.770)
<b>BPF</b>	-0.884 (.1562)		
<b>LF</b>	21.23 (.1082)		

367

368 **Table 2:** Regression coefficients and their associated  $p$ -values (in parentheses) for the

369 effects of  $X_{status}$  on the individual AROC for each qMRI parameter (MTsat, PD, R1 and

370 R2\*) and for volumetric measurements (BPF and LF).


371 \* Results significant at  $p < .05$ , FDR corrected.

372

373 Post-hoc t-tests applied on these significant results for a clearer illustration of the difference

374 in disease status (Figure 4) were all significant at a level of .05.

375



377 **Figure 4:** Violin plots of significant change rates in microstructure with respect to  $X_{status}$ .

378 From left to right: MT in NAWM, MT in NACGM, R2\* in NAWM. \*  $P < .05$ .

379


380 Regarding BPF and LF, their correlation to the disease activity status was not significant (Table  
381 2), suggesting that qMRI parameters are more sensitive to subtle microstructural changes in  
382 NABT over time than global morphological measurements

### 383 **3.3 Analysis of lesion microstructure**

384 The number of enlarging WM lesions between T0 and T1 varied from 2 to 66 across patients,  
385 corresponding on average to 63% ( $\pm 31\%$ ) of the number of initial focal lesions. The number of enlarging  
386 lesions did not significantly differ between patients' disease status groups ( $t(15) = .244, p = .811$ ).  
387 GLMMs found a significant effect of areas (3 lesion regions and NAWM) for MT, R1, R2\* and PD median  
388 (MT:  $F_3 = 35.34, p < .0001$ , PD:  $F_3 = 68.03, p < .0001$ , R1:  $F_3 = 40.26, p < .0001$ , R2\*:  $F_3 =$   
389  $32.32, p < .0001$ ). By contrast, neither time effect (T0 vs T1; MT:  $F_3 = 0.36, p = .5481$ , PD:  $F_3 =$   
390  $1.20, p = .2735$ , R1:  $F_3 = 2.05, p = .1520$ , R2\*:  $F_3 = 2.86, p = .0911$ ), nor the area\*time  
391 interaction (MT:  $F_3 = 0.09, p = .9671$ , PD:  $F_3 = 0.14, p = .9346$ , R1:  $F_3 = 0.14, p = .9331$ , R2\*:  
392  $F_3 = 0.40, p = .7565$ ) were significant, suggesting the microstructural stability of the initial lesion  
393 core. *Post-hoc* tests confirmed significant differences between the four tissue areas.

394 MTsat, R1 and R2\* were significantly larger from FLAIR lesion to initial peripheral lesion, from initial to  
395 later peripheral lesion and from later peripheral lesion to NAWM. The reverse was observed for PD.  
396 The significant difference in parameters between initial and later peripheral lesion at T0 suggests that  
397 subtle microstructural changes appear in the periphery of the initial lesion, months before their  
398 detection as focal FLAIR lesions at T1. Adjusted  $p$ -values appear in Figure 5. Detailed statistical results  
399 of the GLMM's appear in Supplementary data.

400



402 **Figure 5:** Microstructural parameters in NAWM and the 3 lesion-related areas, for each scanning time  
403 T0 and T1. P-values were obtained with *post-hoc* tests on the tissue area effect. \*  $P < .05$ .

404

405

#### 406 **4. Discussion**

407 This longitudinal study followed up volumetric data and qMRI brain metrics (MTsat, PD, R1,  
408 R2\*) in 17 MS patients for a median time interval of 30 months. The main results are threefold.  
409 First, the microstructure of normal appearing brain tissues changes over time and these  
410 modifications concur with, and potentially drive, clinical evolution. This critical finding  
411 suggests that repair mechanism and edema resorption can be monitored *in vivo*. Second, the  
412 microstructure within WM plaques is remarkably heterogeneous. Importantly, at their  
413 periphery, microstructural alterations foreshadow their expansion, as detected by  
414 conventional MRI. Third, as expected, we observed a small but significant brain atrophy and  
415 lesion load increase with time.

416

#### 417 **Quantitative MRI parameter time course within NABT**

418 In this study, we used a multiparameter mapping protocol that was gradually optimized and  
419 validated for multi-centric studies [12]. It provides high-resolution maps of multiple qMRI  
420 parameters from data acquired during a single scanning session of acceptable duration. A  
421 number of cross-sectional studies using a combination of MT, R1, R2\* or PD parameters  
422 reported significant changes in the microstructure of NABT in MS [26, 50-56]. By contrast,  
423 longitudinal analyses of multiparameter qMRI data are scarce. A progressive shortening of  
424 T2/T2\* [57] or increase in R2\* [58-60] was reported within the basal ganglia, suggesting  
425 increased of myelin and/or iron contents as well as edema resorption. Likewise, PD and T1  
426 increased within a year, suggesting a demyelination and/or axonal loss [61]. MTR progressively

427 decreases in NAWM of MS patients over one [62] or two years [63]. These abnormalities tend  
428 to be more pronounced in progressive phenotypes [64] and were associated to a slow, diffuse  
429 and global myelin pathology.

430 Here, we showed that MTsat within NAWM and NACGM and R2\* values within NAWM  
431 increase in clinically stable or improving patients. Because MTsat and R2\* both correlate with  
432 myelin content [14, 30, 31, 65-67], our results suggest repair mechanisms within NABT of  
433 patients who are responding to disease modifying treatments, despite the initial  
434 myelin/axonal loss and independently from WM focal lesion evolution. These results echo  
435 cross-sectional analyses showing that healthy controls (HC) have higher MTsat and R2\* values  
436 within the same tissue classes compared to MS patients [26]. Annual rates of change of R1  
437 and PD within NABT were not significantly associated with the individual clinical status in this  
438 study, although R1 reduction within NABT has already been reported in cross sectional [26,  
439 53, 54] and longitudinal [61] studies comparing MS subjects to HC.

#### 440 441 **Lesion microstructure**

442 Focal inflammatory demyelinating lesions have been extensively characterized and are  
443 traditionally classified as active, chronic active (smoldering) or inactive plaques according to  
444 the presence and distribution of plaque-infiltrating macrophages/microglia [68-70]. Focal WM  
445 pathology is a constantly evolving process including episodes of demyelination and  
446 remyelination but also accumulation of irreversible axonal damage. Age, disease duration,  
447 clinical phenotype as well as disease modifying treatment all contribute to the dynamic nature  
448 of focal WM pathology [69, 71]. This accounts for the large inter- and intra-individual  
449 heterogeneity of MS, which conventional MRI is largely unable to capture. By contrast,  
450 quantitative MRI parameters are sensitive to myelin, axonal as well as iron contents and  
451 appear as promising markers of plaque dynamics. For instance, MTR was shown to sharply

452 decrease within gadolinium enhancing lesions before recovering during the subsequent  
453 months [72-74]. Likewise, reduction of MTR within NAWM, days to weeks before the  
454 formation of a new active lesion was also demonstrated [75, 76], and long-term MTR changes  
455 in WM plaques were observed in relation with disease progression [64, 77]. The present study  
456 broadens the quantitative characterization of plaque dynamics, in keeping with previous  
457 longitudinal studies [57, 78]. Two important findings emerge from the results. First, qMRI  
458 refines lesion segmentation, as compared to the processing based on the sole FLAIR image. In  
459 consequence, the initial lesion revealed by qMRI is typically wider than the plaque detected in  
460 FLAIR. Its periphery is characterized by a decrease in MTsat and R2\* as compared to NAWM,  
461 suggesting an incipient demyelination, reminiscent of the so-called 'periplaques' [79].  
462 Moreover, MTsat, R2\* and R1 values progressively decrease from NAWM to plaque core,  
463 suggesting a centripetal loss of myelin content. Second, plaque microstructure is altered in  
464 plaque periphery before any observable change in conventional MRI signals. This finding  
465 suggests, in keeping with neuropathological observations [69, 71, 80, 81] that subclinical  
466 ongoing inflammation and/or demyelination takes place in the periphery of an active plaque,  
467 well before it is detectable on FLAIR or T1 post-gadolinium sequences. If confirmed on larger  
468 population samples, this finding might significantly modify treatment management in MS  
469 patients.

470 Oddly enough, plaque qMRI parameters did not significantly change across time. Because iron  
471 concentration increases within chronic active or smoldering lesions [82, 83], we were  
472 expecting a progressive increase in R2\* value. This negative result might be due to the small  
473 sample size, the short period of follow up or the limited sensitivity of R2\* to local iron  
474 concentration as compared to the combined use of R2\* and quantitative susceptibility  
475 mapping (QSM) [21].



## 476 **Volumetric Data**

477 CNS atrophy occurs in all stages of MS, since the preclinical phase of the disease and  
478 progresses throughout its course, at a much higher rate than one reported in normal aging  
479 [84-87]. In this study, the annual brain percentage volume loss at the group level was > 0.4%,  
480 which is in line with previous publications [88]. We also showed a significant increase in lesion  
481 fraction. Volumetric data (ARoC's) were highly variable across subjects: changes in BPF range  
482 from -2.52 to 1.17% and LF from -0.78 to 103.06%. This variability arises from a large number  
483 of factors which do or do not relate to MS: age, disease duration, disease phenotype, disease  
484 modifying treatment, circadian rhythm, hydration... [86, 87].  
485 Moreover, annual changes in brain parenchymal fraction as well as lesion fraction only  
486 partially correlated to patients' disease status, in accordance with a large amount of  
487 publications [61, 89]. This highlights the lack of specificity and sensitivity of volumetric  
488 measurements, at least at the individual level.

## 489 **Study limitation**

490 As mentioned earlier, the main limitation of the study was the small size and heterogeneous  
491 aspect of the present dataset. Indeed, it is composed of only 17 patients, with a rather broad  
492 range of characteristics such as age, disease duration, disease phenotype, disease modifying  
493 treatment, etc., which are known to influence the disability state of the patient and thus their  
494 ability to put together repair mechanisms within cerebral tissues [1, 69-71, 90, 91]. In addition,  
495 the time interval between two scanning sessions varied quite a lot across patients (between  
496 14 and 61 months), although it was brought back to an annual rate where possible. All of these  
497 features were imposed by standard clinical follow up. Therefore, these results should not be  
498 over-interpreted but are nevertheless promising and call for a replication with a larger and  
499 more homogeneous or controlled set of MS patients.

## 500 **5. Conclusion**

501 These preliminary results highlight the relevance of multiple qMRI data in the monitoring of  
502 subtle changes within NABT and plaque dynamics in relation with repair or disease  
503 progression. Of course, large scale longitudinal study would be needed to reproduce these  
504 findings and better exploit the full potential of qMRI parameters.

505

## 506 **6. Declarations of interest**

507 None.

508

## 509 **7. Funding**

510 NV, EL and CP are supported by the Fonds de la Recherche Scientifique (F.R.S-FNRS Belgium)

511

512

513

514

## 515 8. References

516 [1] Lassmann, Hans. "Pathology and Disease Mechanisms in Different Stages of  
517 Multiple Sclerosis." *Journal of the Neurological Sciences* 333, no. 1–2 (October 2013):  
518 1–4. <https://doi.org/10.1016/j.jns.2013.05.010>.

519  
520 [2] Trapp, Bruce D., John Peterson, Richard M. Ransohoff, Richard Rudick, Sverre Mörk,  
521 and Lars Bö. "Axonal Transection in the Lesions of Multiple Sclerosis." *New England*  
522 *Journal of Medicine* 338, no. 5 (January 29, 1998): 278–85.  
523 <https://doi.org/10.1056/NEJM199801293380502>.

524  
525 [3] Haider, Lukas, Tobias Zrzavy, Simon Hametner, Romana Höftberger, Francesca  
526 Bagnato, Günther Grabner, Siegfried Trattinig, Sabine Pfeifenbring, Wolfgang Brück,  
527 and Hans Lassmann. "The Topography of Demyelination and Neurodegeneration in the  
528 Multiple Sclerosis Brain." *Brain* 139, no. 3 (March 2016): 807–15.  
529 <https://doi.org/10.1093/brain/awv398>.

530  
531 [4] Kutzelnigg, Alexandra, Claudia F. Lucchinetti, Christine Stadelmann, Wolfgang  
532 Brück, Helmut Rauschka, Markus Bergmann, Manfred Schmidbauer, Joseph E. Parisi,  
533 and Hans Lassmann. "Cortical Demyelination and Diffuse White Matter Injury in  
534 Multiple Sclerosis." *Brain* 128, no. 11 (November 1, 2005): 2705–12.  
535 <https://doi.org/10.1093/brain/awh641>.

536

537 [5] Gh Popescu, Bogdan F, and Claudia F Lucchinetti. "Meningeal and Cortical Grey  
538 Matter Pathology in Multiple Sclerosis." *BMC Neurology* 12, no. 1 (December 2012):  
539 11. <https://doi.org/10.1186/1471-2377-12-11>.

540  
541 [6] Frischer, Josa M., Stephan Bramow, Assunta Dal-Bianco, Claudia F. Lucchinetti,  
542 Helmut Rauschka, Manfred Schmidbauer, Henning Laursen, Per Soelberg Sorensen,  
543 and Hans Lassmann. "The Relation between Inflammation and Neurodegeneration in  
544 Multiple Sclerosis Brains." *Brain* 132, no. 5 (May 2009): 1175–89.  
545 <https://doi.org/10.1093/brain/awp070>.

546  
547 [7] Brown, Robert A., Sridar Narayanan, and Douglas L. Arnold. "Imaging of Repeated  
548 Episodes of Demyelination and Remyelination in Multiple Sclerosis." *NeuroImage:  
549 Clinical* 6 (2014): 20–25. <https://doi.org/10.1016/j.nicl.2014.06.009>.

550  
551 [8] Wang, Chenyu Tim, Michael Barnett, and Yael Barnett. "Imaging the Multiple  
552 Sclerosis Lesion: Insights into Pathogenesis, Progression and Repair." *Current Opinion  
553 in Neurology* 32, no. 3 (June 2019): 338–45.  
554 <https://doi.org/10.1097/WCO.0000000000000698>.

555  
556 [9] Thompson, Alan J, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy  
557 Coetzee, Giancarlo Comi, Jorge Correale, et al. "Diagnosis of Multiple Sclerosis: 2017  
558 Revisions of the McDonald Criteria." *The Lancet Neurology* 17, no. 2 (February 2018):  
559 162–73. [https://doi.org/10.1016/S1474-4422\(17\)30470-2](https://doi.org/10.1016/S1474-4422(17)30470-2).

560

561 [10] Barkhof, Frederik. “The Clinico-Radiological Paradox in Multiple Sclerosis  
562 Revisited:” *Current Opinion in Neurology* 15, no. 3 (June 2002): 239–45.  
563 <https://doi.org/10.1097/00019052-200206000-00003>.

564  
565 [11] Gracien, René-Maxime, Michelle Maiworm, Nadine Brüche, Manoj Shrestha,  
566 Ulrike Nöth, Elke Hattingen, Marlies Wagner, and Ralf Deichmann. “How Stable Is  
567 Quantitative MRI? – Assessment of Intra- and Inter-Scanner-Model Reproducibility  
568 Using Identical Acquisition Sequences and Data Analysis Programs.” *NeuroImage* 207  
569 (February 2020): 116364. <https://doi.org/10.1016/j.neuroimage.2019.116364>.

570  
571 [12] Leutritz, Tobias, Maryam Seif, Gunther Helms, Rebecca S Samson, Armin Curt,  
572 Patrick Freund, and Nikolaus Weiskopf. “Multiparameter Mapping of Relaxation ( R1 ,  
573 R2 \*), Proton Density and Magnetization Transfer Saturation at 3 T : A Multicenter Dual-  
574 vendor Reproducibility and Repeatability Study.” *Human Brain Mapping* 41, no. 15  
575 (October 15, 2020): 4232–47. <https://doi.org/10.1002/hbm.25122>.

576  
577 [13] Tabelow, Karsten, Evelyne Balteau, John Ashburner, Martina F. Callaghan, Bogdan  
578 Draganski, Gunther Helms, Ferath Kherif, et al. “HMRI – A Toolbox for Quantitative MRI  
579 in Neuroscience and Clinical Research.” *NeuroImage* 194 (July 2019): 191–210.  
580 <https://doi.org/10.1016/j.neuroimage.2019.01.029>.

581  
582 [14] Schmierer, Klaus, Francesco Scaravilli, Daniel R. Altmann, Gareth J. Barker, and  
583 David H. Miller. “Magnetization Transfer Ratio and Myelin in Postmortem Multiple

584 Sclerosis Brain.” *Annals of Neurology* 56, no. 3 (September 2004): 407–15.  
585 <https://doi.org/10.1002/ana.20202>.

586  
587 [15] Callaghan, Martina F., Gunther Helms, Antoine Lutti, Siawoosh Mohammadi, and  
588 Nikolaus Weiskopf. “A General Linear Relaxometry Model of  $R_1$  Using Imaging Data:  
589 General Linear Relaxometry Model of  $R_1$ .” *Magnetic Resonance in Medicine* 73, no. 3  
590 (March 2015): 1309–14. <https://doi.org/10.1002/mrm.25210>.

591  
592 [16] Van Waesberghe, J. H. T. M., W. Kamphorst, C. J. A. De Groot, M. A. A. Van  
593 Walderveen, J. A. Castelijns, R. Ravid, G. J. Lycklama a Nijeholt, et al. “Axonal Loss in  
594 Multiple Sclerosis Lesions: Magnetic Resonance Imaging Insights into Substrates of  
595 Disability.” *Annals of Neurology* 46, no. 5 (November 1999): 747–54.  
596 [https://doi.org/10.1002/1531-8249\(199911\)46:5<747::AID-ANA10>3.0.CO;2-4](https://doi.org/10.1002/1531-8249(199911)46:5<747::AID-ANA10>3.0.CO;2-4).

597  
598 [17] Mottershead, J. P., K. Schmierer, M. Clemence, J. S. Thornton, F. Scaravilli, G. J.  
599 Barker, P. S. Tofts, et al. “High Field MRI Correlates of Myelin Content and Axonal  
600 Density in Multiple Sclerosis.” *Journal of Neurology* 250, no. 11 (November 1, 2003):  
601 1293–1301. <https://doi.org/10.1007/s00415-003-0192-3>.

602  
603 [18] Lema, Alfonso, Courtney Bishop, Omar Malik, Miriam Mattoscio, Rehiana Ali,  
604 Richard Nicholas, Paolo A. Muraro, Paul M. Matthews, Adam D. Waldman, and Rexford  
605 D. Newbould. “A Comparison of Magnetization Transfer Methods to Assess Brain and  
606 Cervical Cord Microstructure in Multiple Sclerosis: MT of Brain and c-Spine in MS.”

- 607 *Journal of Neuroimaging* 27, no. 2 (March 2017): 221–26.  
608 <https://doi.org/10.1111/ion.12377>.
- 609
- 610 [19] Helms, Gunther, Henning Dathe, and Peter Dechent. “Modeling the Influence of  
611 TR and Excitation Flip Angle on the Magnetization Transfer Ratio (MTR) in Human Brain  
612 Obtained from 3D Spoiled Gradient Echo MRI.” *Magnetic Resonance in Medicine* 64,  
613 no. 1 (July 2010): 177–85. <https://doi.org/10.1002/mrm.22379>.
- 614
- 615 [20] Bagnato, Francesca, Simon Hametner, Emma Boyd, Verena Endmayr, Yaping Shi,  
616 Vasiliki Ikonomidou, Guanhua Chen, et al. “Untangling the R2\* Contrast in Multiple  
617 Sclerosis: A Combined MRI-Histology Study at 7.0 Tesla.” Edited by Quan Jiang. *PLOS*  
618 *ONE* 13, no. 3 (March 21, 2018): e0193839.  
619 <https://doi.org/10.1371/journal.pone.0193839>.
- 620
- 621 [21] Hametner, Simon, Verena Endmayr, Andreas Deistung, Pilar Palmrich, Max  
622 Prihoda, Evelin Haimburger, Christian Menard, et al. “The Influence of Brain Iron and  
623 Myelin on Magnetic Susceptibility and Effective Transverse Relaxation - A Biochemical  
624 and Histological Validation Study.” *NeuroImage* 179 (October 2018): 117–33.  
625 <https://doi.org/10.1016/j.neuroimage.2018.06.007>.
- 626
- 627 [22] Stüber, Carsten, Markus Morawski, Andreas Schäfer, Christian Labadie, Miriam  
628 Wähnert, Christoph Leuze, Markus Streicher, et al. “Myelin and Iron Concentration in  
629 the Human Brain: A Quantitative Study of MRI Contrast.” *NeuroImage* 93 (June 2014):  
630 95–106. <https://doi.org/10.1016/j.neuroimage.2014.02.026>.

- 631
- 632 [23] Granziera, Cristina, Jens Wuerfel, Frederik Barkhof, Massimiliano Calabrese, Nicola  
633 De Stefano, Christian Enzinger, Nikos Evangelou, et al. “Quantitative Magnetic  
634 Resonance Imaging towards Clinical Application in Multiple Sclerosis.” *Brain* 144, no. 5  
635 (June 22, 2021): 1296–1311. <https://doi.org/10.1093/brain/awab029>.
- 636
- 637 [24] Kolb, Hadar, Martina Absinta, Erin S. Beck, Seung-Kwon Ha, Yeajin Song, Gina  
638 Norato, Irene Cortese, Pascal Sati, Govind Nair, and Daniel S. Reich. “7T MRI  
639 Differentiates Remyelinated from Demyelinated Multiple Sclerosis Lesions.” *Annals of*  
640 *Neurology* 90, no. 4 (October 2021): 612–26. <https://doi.org/10.1002/ana.26194>.
- 641
- 642 [25] Edwards, Luke J., Evgeniya Kirilina, Siawoosh Mohammadi, and Nikolaus Weiskopf.  
643 “Microstructural Imaging of Human Neocortex in Vivo.” *NeuroImage* 182 (November  
644 2018): 184–206. <https://doi.org/10.1016/j.neuroimage.2018.02.055>.
- 645
- 646 [26] Lommers, Emilie, Jessica Simon, Gilles Reuter, Gaël Delrue, Dominique Dive,  
647 Christian Degueldre, Evelyne Balteau, Christophe Phillips, and Pierre Maquet.  
648 “Multiparameter MRI Quantification of Microstructural Tissue Alterations in Multiple  
649 Sclerosis.” *NeuroImage: Clinical* 23 (2019): 101879.  
650 <https://doi.org/10.1016/j.nicl.2019.101879>.
- 651
- 652 [27] Lommers, Emilie, Camille Guillemin, Gilles Reuter, Eve Fouarge, Gaël Delrue,  
653 Fabienne Collette, Christian Degueldre, Evelyne Balteau, Pierre Maquet, and  
654 Christophe Phillips. “VOXEL-BASED Quantitative MRI Reveals Spatial Patterns of Grey



655 Matter Alteration in Multiple Sclerosis.” *Human Brain Mapping* 42, no. 4 (March 2021):  
656 1003–12. <https://doi.org/10.1002/hbm.25274>.

657  
658 [28] Draganski, B., J. Ashburner, C. Hutton, F. Kherif, R.S.J. Frackowiak, G. Helms, and N.  
659 Weiskopf. “Regional Specificity of MRI Contrast Parameter Changes in Normal Ageing  
660 Revealed by Voxel-Based Quantification (VBQ).” *NeuroImage* 55, no. 4 (April 2011):  
661 1423–34. <https://doi.org/10.1016/j.neuroimage.2011.01.052>.

662  
663 [29] Polman, Chris H., Stephen C. Reingold, Brenda Banwell, Michel Clanet, Jeffrey A.  
664 Cohen, Massimo Filippi, Kazuo Fujihara, et al. “Diagnostic Criteria for Multiple Sclerosis:  
665 2010 Revisions to the McDonald Criteria.” *Annals of Neurology* 69, no. 2 (February  
666 2011): 292–302. <https://doi.org/10.1002/ana.22366>.

667  
668 [30] Callaghan, Martina F., Patrick Freund, Bogdan Draganski, Elaine Anderson,  
669 Marinella Cappelletti, Rumana Chowdhury, Joern Diedrichsen, et al. “Widespread Age-  
670 Related Differences in the Human Brain Microstructure Revealed by Quantitative  
671 Magnetic Resonance Imaging.” *Neurobiology of Aging* 35, no. 8 (August 2014): 1862–  
672 72. <https://doi.org/10.1016/j.neurobiolaging.2014.02.008>.

673  
674 [31] Carey, Daniel, Francesco Caprini, Micah Allen, Antoine Lutti, Nikolaus Weiskopf,  
675 Geraint Rees, Martina F. Callaghan, and Frederic Dick. “Quantitative MRI Provides  
676 Markers of Intra-, Inter-Regional, and Age-Related Differences in Young Adult Cortical  
677 Microstructure.” *NeuroImage* 182 (November 2018): 429–40.  
678 <https://doi.org/10.1016/j.neuroimage.2017.11.066>.

679

680 [32] Reuter, Gilles, Emilie Lommers, Evelyne Balteau, Jessica Simon, Christophe Phillips,  
681 Felix Scholtes, Didier Martin, Arnaud Lombard, and Pierre Maquet. "Multiparameter  
682 Quantitative Histological MRI Values in High-Grade Gliomas: A Potential Biomarker of  
683 Tumor Progression." *Neuro-Oncology Practice* 7, no. 6 (December 4, 2020): 646–55.  
684 <https://doi.org/10.1093/nop/npaa047>.

685

686 [33] Depierreux, Frédérique, Eric Parmentier, Laurane Mackels, Katherine Baquero,  
687 Christian Degueldre, Evelyne Balteau, Eric Salmon, et al. "Parkinson's Disease  
688 Multimodal Imaging: F-DOPA PET, Neuromelanin-Sensitive and Quantitative Iron-  
689 Sensitive MRI." *Npj Parkinson's Disease* 7, no. 1 (December 2021): 57.  
690 <https://doi.org/10.1038/s41531-021-00199-2>.

691

692 [34] Nürnberger, Lucas, René-Maxime Gracien, Pavel Hok, Stephanie-Michelle Hof, Udo  
693 Rüb, Helmuth Steinmetz, Rüdiger Hilker, Johannes C. Klein, Ralf Deichmann, and Simon  
694 Baudrexel. "Longitudinal Changes of Cortical Microstructure in Parkinson's Disease  
695 Assessed with T1 Relaxometry." *NeuroImage: Clinical* 13 (2017): 405–14.  
696 <https://doi.org/10.1016/j.nicl.2016.12.025>.

697

698 [35] Klein, J.C., M. Rolinski, L. Griffanti, K. Szewczyk-Krolikowski, F. Baig, C. Ruffmann,  
699 A.R. Groves, R.A.L. Menke, M.T. Hu, and C. Mackay. "Cortical Structural Involvement  
700 and Cognitive Dysfunction in Early Parkinson's Disease." *NMR in Biomedicine* 31, no. 4  
701 (April 2018): e3900. <https://doi.org/10.1002/nbm.3900>.

702

- 703 [36] Lutti, Antoine, Chloe Hutton, Jürgen Finsterbusch, Gunther Helms, and Nikolaus  
704 Weiskopf. "Optimization and Validation of Methods for Mapping of the Radiofrequency  
705 Transmit Field at 3T: Optimized RF Transmit Field Mapping at 3T." *Magnetic Resonance*  
706 *in Medicine* 64, no. 1 (July 2010): 229–38. <https://doi.org/10.1002/mrm.22421>.
- 707
- 708 [37] Lutti, Antoine, Joerg Stadler, Oliver Josephs, Christian Windischberger, Oliver  
709 Speck, Johannes Bernarding, Chloe Hutton, and Nikolaus Weiskopf. "Robust and Fast  
710 Whole Brain Mapping of the RF Transmit Field B1 at 7T." Edited by Wang Zhan. *PLoS*  
711 *ONE* 7, no. 3 (March 12, 2012): e32379.  
712 <https://doi.org/10.1371/journal.pone.0032379>.
- 713
- 714 [38] Schmidt, Paul, Christian Gaser, Milan Arsic, Dorothea Buck, Annette Förchler,  
715 Achim Berthele, Muna Hoshi, et al. "An Automated Tool for Detection of FLAIR-  
716 Hyperintense White-Matter Lesions in Multiple Sclerosis." *NeuroImage* 59, no. 4  
717 (February 2012): 3774–83. <https://doi.org/10.1016/j.neuroimage.2011.11.032>.
- 718
- 719 [39] Weiskopf, Nikolaus, Martina F. Callaghan, Oliver Josephs, Antoine Lutti, and  
720 Siawoosh Mohammadi. "Estimating the Apparent Transverse Relaxation Time (R2\*)  
721 from Images with Different Contrasts (ESTATICS) Reduces Motion Artifacts." *Frontiers*  
722 *in Neuroscience* 8 (September 10, 2014). <https://doi.org/10.3389/fnins.2014.00278>.
- 723
- 724 [40] Preibisch, C., and R. Deichmann. "Influence of RF Spoiling on the Stability and  
725 Accuracy of  $T_1$  Mapping Based on Spoiled FLASH with Varying Flip Angles: Influence of

- 726 RF Spoiling on  $T_1$  Mapping.” *Magnetic Resonance in Medicine* 61, no. 1 (January 2009):  
727 125–35. <https://doi.org/10.1002/mrm.21776>.
- 728
- 729 [41] Ashburner, John. “Symmetric Diffeomorphic Modeling of Longitudinal Structural  
730 MRI.” *Frontiers in Neuroscience* 6 (2013). <https://doi.org/10.3389/fnins.2012.00197>.
- 731
- 732 [42] Ashburner, John, and Karl J. Friston. “Unified Segmentation.” *NeuroImage* 26, no.  
733 3 (July 2005): 839–51. <https://doi.org/10.1016/j.neuroimage.2005.02.018>.
- 734
- 735 [43] Lorio, S., S. Fresard, S. Adaszewski, F. Kherif, R. Chowdhury, R.S. Frackowiak, J.  
736 Ashburner, et al. “New Tissue Priors for Improved Automated Classification of  
737 Subcortical Brain Structures on MRI.” *NeuroImage* 130 (April 2016): 157–66.  
738 <https://doi.org/10.1016/j.neuroimage.2016.01.062>.
- 739
- 740 [44] Andersen, Sarah M., Steven Z. Rapcsak, and Pélagie M. Beeson. “Cost Function  
741 Masking during Normalization of Brains with Focal Lesions: Still a Necessity?”  
742 *NeuroImage* 53, no. 1 (October 2010): 78–84.  
743 <https://doi.org/10.1016/j.neuroimage.2010.06.003>.
- 744
- 745 [45] Moon, Nathan, Elizabeth Bullitt, Koen van Leemput, and Guido Gerig. “Automatic  
746 Brain and Tumor Segmentation.” In *Medical Image Computing and Computer-Assisted  
747 Intervention — MICCAI 2002*, edited by Takeyoshi Dohi and Ron Kikinis, 2488:372–79.  
748 Lecture Notes in Computer Science. Berlin, Heidelberg: Springer Berlin Heidelberg,  
749 2002. [https://doi.org/10.1007/3-540-45786-0\\_46](https://doi.org/10.1007/3-540-45786-0_46).

750

751 [46] Pandit, Lekha. "No Evidence of Disease Activity (NEDA) in Multiple Sclerosis -  
752 Shifting the Goal Posts." *Annals of Indian Academy of Neurology* 22, no. 3 (2019): 261.  
753 [https://doi.org/10.4103/aian.AIAN\\_159\\_19](https://doi.org/10.4103/aian.AIAN_159_19).

754

755 [47] Wiendl, Heinz, and Sven G. Meuth. "Pharmacological Approaches to Delaying  
756 Disability Progression in Patients with Multiple Sclerosis." *Drugs* 75, no. 9 (June 2015):  
757 947–77. <https://doi.org/10.1007/s40265-015-0411-0>.

758

759 [48] Anderson, Marti J. "Permutation Tests for Univariate or Multivariate Analysis of  
760 Variance and Regression." *Canadian Journal of Fisheries and Aquatic Sciences* 58, no. 3  
761 (March 1, 2001): 626–39. <https://doi.org/10.1139/f01-004>.

762

763 [49] Yoav Benjamini and Yosef Hochberg. "Controlling the False Discovery Rate: a  
764 Practical and Powerful Approach to Multiple Testing" *Journal of the Royal Statistical*  
765 *Society. Series B (Methodological)*, Vol. 57, No.1 (1995), 289-300.

766

767

768

769 [50] Andica, Christina, Akifumi Hagiwara, Koji Kamagata, Kazumasa Yokoyama, Keigo  
770 Shimoji, Asami Saito, Yuki Takenaka, et al. "Gray Matter Alterations in Early and Late  
771 Relapsing-Remitting Multiple Sclerosis Evaluated with Synthetic Quantitative Magnetic  
772 Resonance Imaging." *Scientific Reports* 9, no. 1 (December 2019): 8147.  
773 <https://doi.org/10.1038/s41598-019-44615-3>.

774

775 [51] Bonnier, Guillaume, Alexis Roche, David Romascano, Samanta Simioni, Djalel  
776 Meskaldji, David Rotzinger, Ying-Chia Lin, et al. “Advanced MRI Unravels the Nature of  
777 Tissue Alterations in Early Multiple Sclerosis.” *Annals of Clinical and Translational*  
778 *Neurology* 1, no. 6 (June 2014): 423–32. <https://doi.org/10.1002/acn3.68>.

779

780 [52] Engström, Maria, Jan B. M. Warntjes, Anders Tisell, Anne-Marie Landtblom, and  
781 Peter Lundberg. “Multi-Parametric Representation of Voxel-Based Quantitative  
782 Magnetic Resonance Imaging.” Edited by Friedemann Paul. *PLoS ONE* 9, no. 11  
783 (November 13, 2014): e111688. <https://doi.org/10.1371/journal.pone.0111688>.

784

785 [53] Gracien, René-Maxime, Alina Jurcoane, Marlies Wagner, Sarah C. Reitz, Christoph  
786 Mayer, Steffen Volz, Stephanie-Michelle Hof, et al. “Multimodal Quantitative MRI  
787 Assessment of Cortical Damage in Relapsing-Remitting Multiple Sclerosis: Cortical  
788 Quantitative MRI in RRMS.” *Journal of Magnetic Resonance Imaging* 44, no. 6  
789 (December 2016): 1600–1607. <https://doi.org/10.1002/jmri.25297>.

790

791 [54] Neema, Mohit, James Stankiewicz, Ashish Arora, Venkata S.R. Dandamudi,  
792 Courtney E. Batt, Zachary D. Guss, Ali Al-Sabbagh, and Rohit Bakshi. “T1- and T2-Based  
793 MRI Measures of Diffuse Gray Matter and White Matter Damage in Patients with  
794 Multiple Sclerosis.” *Journal of Neuroimaging* 17 (April 2007): 16S-21S.  
795 <https://doi.org/10.1111/j.1552-6569.2007.00131.x>.

796

797 [55] Reitz, Sarah C., Stephanie-Michelle Hof, Vinzenz Fleischer, Alla Brodski, Adriane  
798 Gröger, René-Maxime Gracien, Amgad Droby, et al. “Multi-Parametric Quantitative  
799 MRI of Normal Appearing White Matter in Multiple Sclerosis, and the Effect of Disease  
800 Activity on T2.” *Brain Imaging and Behavior* 11, no. 3 (June 2017): 744–53.  
801 <https://doi.org/10.1007/s11682-016-9550-5>.

802  
803 [56] Stevenson, V.L, G.J.M Parker, G.J Barker, K Birnie, P.S Tofts, D.H Miller, and A.J  
804 Thompson. “Variations in T1 and T2 Relaxation Times of Normal Appearing White  
805 Matter and Lesions in Multiple Sclerosis.” *Journal of the Neurological Sciences* 178, no.  
806 2 (September 2000): 81–87. [https://doi.org/10.1016/S0022-510X\(00\)00339-7](https://doi.org/10.1016/S0022-510X(00)00339-7).

807  
808 [57] Bonnier, Guillaume, Benedicte Maréchal, Mário João Fartaria, Pavel Falkowskiy,  
809 José P. Marques, Samanta Simioni, Myriam Schluep, et al. “The Combined  
810 Quantification and Interpretation of Multiple Quantitative Magnetic Resonance  
811 Imaging Metrics Enlightens Longitudinal Changes Compatible with Brain Repair in  
812 Relapsing-Remitting Multiple Sclerosis Patients.” *Frontiers in Neurology* 8 (September  
813 27, 2017): 506. <https://doi.org/10.3389/fneur.2017.00506>.

814  
815 [58] Elkady, Ahmed M., Dana Cobzas, Hongfu Sun, Gregg Blevins, and Alan H. Wilman.  
816 “Discriminative Analysis of Regional Evolution of Iron and Myelin/Calcium in Deep Gray  
817 Matter of Multiple Sclerosis and Healthy Subjects: Analysis of Iron and Myelin in MS.”  
818 *Journal of Magnetic Resonance Imaging* 48, no. 3 (September 2018): 652–68.  
819 <https://doi.org/10.1002/jmri.26004>.

820

- 821 [59] Elkady, Ahmed M., Dana Cobzas, Hongfu Sun, Peter Seres, Gregg Blevins, and Alan  
822 H. Wilman. "Five Year Iron Changes in Relapsing-Remitting Multiple Sclerosis Deep Gray  
823 Matter Compared to Healthy Controls." *Multiple Sclerosis and Related Disorders* 33  
824 (August 2019): 107–15. <https://doi.org/10.1016/j.msard.2019.05.028>.
- 825
- 826 [60] Khalil, M., C. Langkammer, A. Pichler, D. Pinter, T. Gatteringer, G. Bachmaier, S.  
827 Ropele, S. Fuchs, C. Enzinger, and F. Fazekas. "Dynamics of Brain Iron Levels in Multiple  
828 Sclerosis: A Longitudinal 3T MRI Study." *Neurology* 84, no. 24 (June 16, 2015): 2396–  
829 2402. <https://doi.org/10.1212/WNL.0000000000001679>.
- 830
- 831 [61] Gracien, René-Maxime, Sarah C. Reitz, Stephanie-Michelle Hof, Vinzenz Fleischer,  
832 Amgad Droby, Mathias Wahl, Helmuth Steinmetz, Sergiu Groppa, Ralf Deichmann, and  
833 Johannes C. Klein. "Longitudinal Quantitative MRI Assessment of Cortical Damage in  
834 Multiple Sclerosis: A Pilot Study: Longitudinal Cortical QMRI in MS." *Journal of Magnetic*  
835 *Resonance Imaging* 46, no. 5 (November 2017): 1485–90.  
836 <https://doi.org/10.1002/jmri.25685>.
- 837
- 838 [62] Laule, Cornelia, I. M. Vavasour, K. P. Whittall, J. Oger, D. W. Paty, D. K. B. Li, A. L.  
839 MacKay, and D. L. Arnold. "Evolution of Focal and Diffuse magnetisation Transfer  
840 Abnormalities in Multiple Sclerosis." *Journal of Neurology* 250, no. 8 (August 2003):  
841 924–31. <https://doi.org/10.1007/s00415-003-1115-z>.
- 842
- 843 [63] Hayton, T., J. Furby, K. J. Smith, D. R. Altmann, R. Brenner, J. Chataway, K. Hunter,  
844 D. J. Tozer, D. H. Miller, and R. Kapoor. "Longitudinal Changes in Magnetisation Transfer



845 Ratio in Secondary Progressive Multiple Sclerosis: Data from a Randomised Placebo  
846 Controlled Trial of Lamotrigine.” *Journal of Neurology* 259, no. 3 (March 2012): 505–14.  
847 <https://doi.org/10.1007/s00415-011-6212-9>.

848  
849 [64] Rocca, Maria A, Giovanna Mastronardo, Mariemma Rodegher, Giancarlo Comi, and  
850 Massimo Filippi. “Long-Term Changes of Magnetization Transfer-Derived Measures  
851 from Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis,”  
852 *AJNR Am J Neuroradiol* 20 (1999):821–827

853  
854 [65] Weiskopf, Nikolaus, Siawoosh Mohammadi, Antoine Lutti, and Martina F.  
855 Callaghan. “Advances in MRI-Based Computational Neuroanatomy: From  
856 Morphometry to in-Vivo Histology.” *Current Opinion in Neurology* 28, no. 4 (August  
857 2015): 313–22. <https://doi.org/10.1097/WCO.0000000000000222>.

858  
859 [66] Hametner, Simon, Verena Endmayr, Andreas Deistung, Pilar Palmrich, Max  
860 Prihoda, Evelin Haimburger, Christian Menard, et al. “The Influence of Brain Iron and  
861 Myelin on Magnetic Susceptibility and Effective Transverse Relaxation - A Biochemical  
862 and Histological Validation Study.” *NeuroImage* 179 (October 2018): 117–33.  
863 <https://doi.org/10.1016/j.neuroimage.2018.06.007>.

864  
865 [67] Mangeat, G., S.T. Govindarajan, C. Mainero, and J. Cohen-Adad. “Multivariate  
866 Combination of Magnetization Transfer, T 2 \* and B0 Orientation to Study the Myelo-  
867 Architecture of the in Vivo Human Cortex.” *NeuroImage* 119 (October 2015): 89–102.  
868 <https://doi.org/10.1016/j.neuroimage.2015.06.033>.

869

870 [68] Dutta, R., and B. D. Trapp. "Pathogenesis of Axonal and Neuronal Damage in  
871 Multiple Sclerosis." *Neurology* 68, no. Issue 22, Supplement 3 (May 29, 2007): S22–31.  
872 <https://doi.org/10.1212/01.wnl.0000275229.13012.32>.

873

874 [69] Frischer, Josa M., Stephen D. Weigand, Yong Guo, Nilufer Kale, Joseph E. Parisi,  
875 Istvan Pirko, Jay Mandrekar, et al. "Clinical and Pathological Insights into the Dynamic  
876 Nature of the White Matter Multiple Sclerosis Plaque: Dynamic Nature of MS Plaque."  
877 *Annals of Neurology* 78, no. 5 (November 2015): 710–21.  
878 <https://doi.org/10.1002/ana.24497>.

879

880 [70] Lassmann, Hans, Wolfgang Brück, and Claudia Lucchinetti. "Heterogeneity of  
881 Multiple Sclerosis Pathogenesis: Implications for Diagnosis and Therapy." *Trends in*  
882 *Molecular Medicine* 7, no. 3 (March 2001): 115–21. [https://doi.org/10.1016/S1471-](https://doi.org/10.1016/S1471-4914(00)01909-2)  
883 [4914\(00\)01909-2](https://doi.org/10.1016/S1471-4914(00)01909-2).

884

885 [71] Lucchinetti, Claudia, Wolfgang Brück, Joseph Parisi, Bernd Scheithauer, Moses  
886 Rodriguez, and Hans Lassmann. "Heterogeneity of Multiple Sclerosis Lesions:  
887 Implications for the Pathogenesis of Demyelination." *Annals of Neurology* 47, no. 6  
888 (June 2000): 707–17. [https://doi.org/10.1002/1531-8249\(200006\)47:6<707::AID-](https://doi.org/10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q)  
889 [ANA3>3.0.CO;2-Q](https://doi.org/10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q).

890

891 [72] Dousset, Vincent, Annick Gayou, Bruno Brochet, and Jean-Marie Caille. "Early  
892 Structural Changes in Acute MS Lesions Assessed by Serial Magnetization Transfer

- 893 Studies.” *Neurology* 51, no. 4 (October 1998): 1150–55.  
894 <https://doi.org/10.1212/WNL.51.4.1150>.
- 895
- 896 [73] Levesque, Ives R., Paul S. Giacomini, Sridar Narayanan, Luciana T. Ribeiro, John G.  
897 Sled, Doug L. Arnold, and G. Bruce Pike. “Quantitative Magnetization Transfer and  
898 Myelin Water Imaging of the Evolution of Acute Multiple Sclerosis Lesions: Quantitative  
899 MT and T<sub>2</sub> in Acute MS Lesions.” *Magnetic Resonance in Medicine* 63, no. 3 (March  
900 2010): 633–40. <https://doi.org/10.1002/mrm.22244>.
- 901
- 902 [74] Elskamp, Ij van den, DI Knol, H. Vrenken, G. Karas, A. Meijerman, M. Filippi, L.  
903 Kappos, et al. “Lesional Magnetization Transfer Ratio: A Feasible Outcome for  
904 Remyelinating Treatment Trials in Multiple Sclerosis.” *Multiple Sclerosis Journal* 16, no.  
905 6 (June 2010): 660–69. <https://doi.org/10.1177/1352458510364630>.
- 906
- 907 [75] Filippi, Massimo, Maria A. Rocca, Gianvito Martino, Mark A. Horsfield, and  
908 Giancarlo Comi. “Magnetization Transfer Changes in the Normal Appearing White  
909 Matter Precede the Appearance of Enhancing Lesions in Patients with Multiple  
910 Sclerosis.” *Annals of Neurology* 43, no. 6 (June 1998): 809–14.  
911 <https://doi.org/10.1002/ana.410430616>.
- 912
- 913 [76] Fazekas, F, S Ropele, C Enzinger, T Seifert, and S Strasser-Fuchs. “Quantitative  
914 Magnetization Transfer Imaging of Pre-Lesional White-Matter Changes in Multiple  
915 Sclerosis.” *Multiple Sclerosis Journal* 8, no. 6 (December 2002): 479–84.  
916 <https://doi.org/10.1191/1352458502ms860oa>.

917

918 [77] Zheng, Yufan, Jar-Chi Lee, Richard Rudick, and Elizabeth Fisher. “Long-Term  
919 Magnetization Transfer Ratio Evolution in Multiple Sclerosis White Matter Lesions:  
920 Long-Term MTR Evolution in MS WM Lesions.” *Journal of Neuroimaging* 28, no. 2  
921 (March 2018): 191–98. <https://doi.org/10.1111/jon.12480>.

922

923 [78] Chawla, Sanjeev, Ilya Kister, Tim Sinnecker, Jens Wuerfel, Jean-Christophe Brisset,  
924 Friedemann Paul, and Yulin Ge. “Longitudinal Study of Multiple Sclerosis Lesions Using  
925 Ultra-High Field (7T) Multiparametric MR Imaging.” Edited by Quan Jiang. *PLOS ONE* 13,  
926 no. 9 (September 13, 2018): e0202918.  
927 <https://doi.org/10.1371/journal.pone.0202918>.

928

929 [79] Lieury, Alice, Marie Chanal, Géraldine Androdias, Richard Reynolds, Sylvie Cavagna,  
930 Pascale Giraudon, Christian Confavreux, and Serge Nataf. “Tissue Remodeling in  
931 Periplaque Regions of Multiple Sclerosis Spinal Cord Lesions: Glia Remodeling in MS  
932 Spinal Cord.” *Glia* 62, no. 10 (October 2014): 1645–58.  
933 <https://doi.org/10.1002/glia.22705>.

934

935 [80] Kuhlmann, Tanja, Samuel Ludwin, Alexandre Prat, Jack Antel, Wolfgang Brück, and  
936 Hans Lassmann. “An Updated Histological Classification System for Multiple Sclerosis  
937 Lesions.” *Acta Neuropathologica* 133, no. 1 (January 2017): 13–24.  
938 <https://doi.org/10.1007/s00401-016-1653-y>.

939

940 [81] Lassmann, Hans, Wolfgang Brück, and Claudia F. Lucchinetti. “The  
941 Immunopathology of Multiple Sclerosis: An Overview.” *Brain Pathology* 17, no. 2 (April  
942 2007): 210–18. <https://doi.org/10.1111/j.1750-3639.2007.00064.x>.

943  
944 [82] Dal-Bianco, Assunta, Günther Grabner, Claudia Kronnerwetter, Michael Weber,  
945 Romana Höftberger, Thomas Berger, Eduard Auff, et al. “Slow Expansion of Multiple  
946 Sclerosis Iron Rim Lesions: Pathology and 7 T Magnetic Resonance Imaging.” *Acta*  
947 *Neuropathologica* 133, no. 1 (January 2017): 25–42. [https://doi.org/10.1007/s00401-](https://doi.org/10.1007/s00401-016-1636-z)  
948 [016-1636-z](https://doi.org/10.1007/s00401-016-1636-z).

949  
950 [83] Elliott, Colm, Jerry S Wolinsky, Stephen L Hauser, Ludwig Kappos, Frederik Barkhof,  
951 Corrado Bernardoni, Wei Wei, Shibeshih Belachew, and Douglas L Arnold. “Slowly  
952 Expanding/Evolving Lesions as a Magnetic Resonance Imaging Marker of Chronic Active  
953 Multiple Sclerosis Lesions.” *Multiple Sclerosis Journal* 25, no. 14 (December 2019):  
954 1915–25. <https://doi.org/10.1177/1352458518814117>.

955  
956 [84] De Stefano, N., A. Giorgio, M. Battaglini, M. Rovaris, M. P. Sormani, F. Barkhof, T.  
957 Korteweg, et al. “Assessing Brain Atrophy Rates in a Large Population of Untreated  
958 Multiple Sclerosis Subtypes.” *Neurology* 74, no. 23 (June 8, 2010): 1868–76.  
959 <https://doi.org/10.1212/WNL.0b013e3181e24136>.

960  
961 [85] Eshaghi, Arman, Ferran Prados, Wallace J. Brownlee, Daniel R. Altmann, Carmen  
962 Tur, M. Jorge Cardoso, Floriana De Angelis, et al. “Deep Gray Matter Volume Loss Drives

963 Disability Worsening in Multiple Sclerosis: Deep Gray Matter Volume Loss.” *Annals of*  
964 *Neurology* 83, no. 2 (February 2018): 210–22. <https://doi.org/10.1002/ana.25145>.

965

966 [86] Bermel, Robert A, and Rohit Bakshi. “The Measurement and Clinical Relevance of  
967 Brain Atrophy in Multiple Sclerosis.” *The Lancet Neurology* 5, no. 2 (February 2006):  
968 158–70. [https://doi.org/10.1016/S1474-4422\(06\)70349-0](https://doi.org/10.1016/S1474-4422(06)70349-0).

969

970 [87] Zivadinov, R., A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K.  
971 Racke, M. G. Dwyer, E. M. Frohman, and O. Khan. “Mechanisms of Action of Disease-  
972 Modifying Agents and Brain Volume Changes in Multiple Sclerosis.” *Neurology* 71, no.  
973 2 (July 8, 2008): 136–44. <https://doi.org/10.1212/01.wnl.0000316810.01120.05>.

974

975 [88] De Stefano, Nicola, Maria Laura Stromillo, Antonio Giorgio, Maria Letizia Bartolozzi,  
976 Marco Battaglini, Mariella Baldini, Emilio Portaccio, Maria Pia Amato, and Maria Pia  
977 Sormani. “Establishing Pathological Cut-Offs of Brain Atrophy Rates in Multiple  
978 Sclerosis.” *Journal of Neurology, Neurosurgery & Psychiatry*, April 22, 2015, jnnp-2014-  
979 309903. <https://doi.org/10.1136/jnnp-2014-309903>.

980

981 [89] on behalf of the MAGNIMS study group, Christian Enzinger, Frederik Barkhof, Olga  
982 Ciccarelli, Massimo Filippi, Ludwig Kappos, Maria A. Rocca, et al. “Nonconventional MRI  
983 and Microstructural Cerebral Changes in Multiple Sclerosis.” *Nature Reviews Neurology*  
984 11, no. 12 (December 2015): 676–86. <https://doi.org/10.1038/nrneurol.2015.194>.

985

986 [90] Bodini, Benedetta, Mattia Veronese, Daniel García-Lorenzo, Marco Battaglini,  
987 Emilie Poirion, Audrey Chardain, Léorah Freeman, et al. “Dynamic Imaging of Individual  
988 Remyelination Profiles in Multiple Sclerosis.” *Annals of Neurology* 79, no. 5 (May 2016):  
989 726–38. <https://doi.org/10.1002/ana.24620>.

990  
991 [91] Patrikios, P., C. Stadelmann, A. Kutzelnigg, H. Rauschka, M. Schmidbauer, H.  
992 Laursen, P. S. Sorensen, W. Bruck, C. Lucchinetti, and H. Lassmann. “Remyelination Is  
993 Extensive in a Subset of Multiple Sclerosis Patients.” *Brain* 129, no. 12 (June 9, 2006):  
994 3165–72. <https://doi.org/10.1093/brain/awl217>.

995